82 related articles for article (PubMed ID: 8366571)
1. [A comparative study of VEPA and ACOMEP-BD regimen for the patients with non-Hodgkin's lymphoma].
Kanamori H; Tanabe J; Okamoto R; Tamura T; Fujita H; Murata T; Hashimoto Y; Harano H; Matsuzaki M; Motomura S
Rinsho Ketsueki; 1993 Jun; 34(6):697-704. PubMed ID: 8366571
[TBL] [Abstract][Full Text] [Related]
2. [Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, prednisolone (VEPA) in non-Hodgkin's lymphoma, with special reference to correlation of surface phenotype with response and survival].
Chubachi A; Miura AB; Yamaguchi A; Nishimura S
Gan To Kagaku Ryoho; 1988 Jul; 15(7):2057-63. PubMed ID: 3293535
[TBL] [Abstract][Full Text] [Related]
3. [Combination chemotherapy with cyclophosphamide, adriamycin, vincristine and prednisolone (VEPA) for non-Hodgkin's lymphoma].
Saaki A; Yokomatsu Y; Kojima K; Yoshikawa T; Sannomiya Y; Tatsumi J; Hashimoto K; Park K; Kawarabayashi K; Yoshikawa C
Gan To Kagaku Ryoho; 1986 Jan; 13(1):65-9. PubMed ID: 3753642
[TBL] [Abstract][Full Text] [Related]
4. Major prognostic factors of adult patients with advanced B-cell lymphoma treated with vincristine, cyclophosphamide, prednisone and doxorubicin (VEPA) or VEPA plus methotrexate (VEPA-M).
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ogawa M; Tominaga S; Tsugane S; Minato K
Jpn J Clin Oncol; 1988 Jun; 18(2):113-24. PubMed ID: 3379782
[TBL] [Abstract][Full Text] [Related]
5. [Low-grade non-Hodgkin's lymphoma: intensive combined chemotherapy].
Hattori M; Motomura S; Tomita N; Taguchi J; Tanabe J; Sakai R; Fujisawa S; Fukawa H; Kanamori H; Mouri H; Maruta A; Kodama F; Okubo T
Rinsho Ketsueki; 1996 Feb; 37(2):101-8. PubMed ID: 8852026
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
7. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
[TBL] [Abstract][Full Text] [Related]
9. 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: results of a pilot study of the German Hodgkin's Lymphoma Study Group.
Sieber M; Bredenfeld H; Josting A; Reineke T; Rueffer U; Koch T; Naumann R; Boissevain F; Koch P; Worst P; Soekler M; Eich H; Müller-Hermelink HK; Franklin J; Paulus U; Wolf J; Engert A; Diehl V;
J Clin Oncol; 2003 May; 21(9):1734-9. PubMed ID: 12721249
[TBL] [Abstract][Full Text] [Related]
10. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
Gobbi PG; Ghirardelli ML; Avanzini P; Baldini L; Quarta G; Stelitano C; Broglia C; Loni C; Silingardi V; Ascari E
Haematologica; 2000 Mar; 85(3):263-8. PubMed ID: 10702814
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcome and prognostic factors for relapse after high-dose chemotherapy and peripheral blood stem cell rescue for patients with poor risk high grade non-Hodgkin's lymphoma.
Lee SM; Ryder WD; Clemons MJ; Morgenstern GR; Chang J; Scarffe JH; Radford JA
Bone Marrow Transplant; 1999 Aug; 24(3):271-7. PubMed ID: 10455365
[TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
13. [Treatment results and prognostic significance of selected clinical and laboratory features in children diagnosed with malignant lymphoma].
Kamieńska E
Ann Acad Med Stetin; 1996; 42():105-22. PubMed ID: 9199116
[TBL] [Abstract][Full Text] [Related]
14. [Combination chemotherapy of diffuse large-cell non-Hodgkin's lymphoma--superiority of the adriamycin combination].
Tada A; Ohnoshi T; Hayashi K; Ueoka H; Ueno K; Murashima M; Mizuta J; Yoshida M; Kimura I
Gan To Kagaku Ryoho; 1987 Sep; 14(9):2692-6. PubMed ID: 2443077
[TBL] [Abstract][Full Text] [Related]
15. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
van Imhoff GW; van der Holt B; Mackenzie MA; Van't Veer MB; Wijermans PW; Ossenkoppele GJ; Schouten HC; Sonneveld P; Steijaert MM; Kluin PM; Kluin-Nelemans HC; Verdonck LF;
J Clin Oncol; 2005 Jun; 23(16):3793-801. PubMed ID: 15809447
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
[TBL] [Abstract][Full Text] [Related]
17. [THP-adriamycin-based combination chemotherapy in the treatment of non-Hodgkin's lymphoma].
Ishige K; Matsue K; Tsukuda K; Sakai C; Takagi T
Gan To Kagaku Ryoho; 1992 Oct; 19(12):2037-40. PubMed ID: 1417012
[TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy of a quadruple combination chemotherapy with ACNU, adriamycin, methotrexate, and prednisolone for patients with non-Hodgkin's lymphoma, who were refractory to VEPA (P) treatment].
Niitsu H; Fukuda M; Fukuda S; Takatsu H; Nakayama Y; Hirokawa M; Mamiya S; Miura I; Takahashi F; Yoshida K
Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 1):2585-9. PubMed ID: 6594975
[TBL] [Abstract][Full Text] [Related]
19. Combined chemotherapy with carmustine, doxorubicin, etoposide, vincristine, and cyclophosphamide plus mitoxantrone, cytarabine and methotrexate with citrovorum factor for the treatment of aggressive non-Hodgkin lymphoma: a long-term follow-up study.
Rigacci L; Carrai V; Nassi L; Alterini R; Longo G; Bernardi F; Bosi A
Cancer; 2005 Mar; 103(5):970-7. PubMed ID: 15666323
[TBL] [Abstract][Full Text] [Related]
20. Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.
Shimoyama M; Ota K; Kikuchi M; Yunoki K; Konda S; Takatsuki K; Ichimaru M; Ogawa M; Kimura I; Tominaga S
J Clin Oncol; 1988 Jan; 6(1):128-41. PubMed ID: 2891797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
